Mok_subbed.qxp 30/3/09 9:21 am Page 40
Lung Cancer
1. American Cancer Society, Cancer statistics, 2008 777–84. safety of bevacizumab in combination with chemotherapy or
presentation, accessed 17 September 2008. Available at: 21. Herbst RS, Giaccone G, et al., Gefitinib in combination with erlotinib compared with chemotherapy alone for treatment of
www.cancer.org/ downloads/ STT/Cancer_Statistics_2008.asp paclitaxel and carboplatin in advanced non-small-cell lung recurrent or refractory non small-cell lung cancer, J Clin
2. Yang L, Parkin D, et al., Estimates of cancer incidence in cancer: A phase III trial – INTACT2, J Clin Oncol, 2004;22: Oncol, 2007;25:4743–50.
China for 2000 and projections for 2005, Cancer Epidemiol 785–94. 39. Hainsworth J, Herbst R, A phase III, multicenter, placebo-
Biomarkers Prev, 2005;14(1):243–50. 22. Mok T, Wu YL, Thongpraser S, et al., Phase III, randomised, controlled, double-blind, randomized clinical trial to evaluate
3. National Comprehensive Cancer Network, NCCN clinical open-label, first-line study of gefitinib (G) vs the efficacy of bevacizumab (Avastin
®
) in combination with
practice guidelines in oncology: Non-small cell lung cancer. carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) erlotinib (Tarceva
®
) compared with erlotinib alone for
Version 1.2009, accessed 17 September 2008. Available at: with advanced non-small-cell lung cancer (NSCLC) (IPASS), treatment of advanced non-small cell lung cancer after failure
www.nccn.org/ professionals/physician_gls/PDF/nscl.pdf Ann Oncol, 2008;19(Suppl. 8):viii1–viii4, abstract LBA2. of standard first-line chemotherapy (BETA). Paper presented
4. NSCLC Collaborative Group, Chemotherapy in non-small cell 23. Davies AM, Ho C, et al., Pharmacodynamic separation of at 2008 Chicago Multidisciplinary Symposium in Thoracic
lung cancer: a meta-analysis using updated data on epidermal growth factor receptor tyrosine kinase inhibitors Oncology, 13–15 November, 2008.
individual patients from 52 randomised clinical trials, BMJ, and chemotherapy in non-small-cell lung cancer, Clin Lung 40. Kim ES, Mauer AM, et al., A phase II study of cetuximab, an
1995;311: 899–909. Cancer, 2006;7:385–8. epidermal growth factor receptor (EGFR) blocking antibody,
5. Ohe Y, Ohashi Y, et al., Randomized phase III study of 24. Solit DB, She Y, et al., Pulsatile administration of the in combination with docetaxel in chemotherapy
cisplatin plus irinotecan versus carboplatin plus paclitaxel, epidermal growth factor receptor inhibitor gefitinib is refractory/resistant patients with advanced non-small cell
cisplatin plus gemcitabine, and cisplatin plus vinorelbine for significantly more effective than continuous dosing for lung cancer: Final report, Proc Am Soc Clin Oncol, 2003;22:
advanced non-small-cell lung cancer: Four-Arm Cooperative sensitizing tumors to paclitaxel, Clin Cancer Res, Abstract 642.
Study in Japan, Ann Oncol, 2007;18(2):317–23. 2005;11:1983–9. 41. Di Maio M, Perrone F, et al., Individual patient data meta-
6. Fossella F, Pereira JR, et al., Randomized, multinational, 25. Lee JS, Ignacio J, et al., FAST-ACT: A phase II randomized analysis of docetaxel administered once every three weeks
phase III study of docetaxel plus platinum combinations double-blind trial of sequential erlotinib and chemotherapy as compared with once every week second-line treatment of
versus vinorelbine plus cisplatin for advanced non-small-cell first-line treatment in patients (pts) with stage IIIB/IV non- advanced non-small-cell lung cancer, J Clin Oncol, 2007;25:
lung cancer: the TAX 326 study group, J Clin Oncol, small cell lung cancer (NSCLC), J Clin Oncol, 2008;26(15S): 1377–82.
2003;21(16): 3016–24. Abstract 8031. 42. Mukohara T, Takeda K, et al., Japanese experience with
7. Smit EF, van Meerbeeck JP, et al., Three-arm randomized 26. Pirker R, Szczesna A, et al., FLEX: a randomized, multicentre, second-line chemotherapy with low-dose (60 mg/m
2
)
study of two cisplatin-based regimens and paclitaxel plus phase III study of cetuximab in combination with docetaxel in patients with advanced non-small-cell lung
gemcitabine in advanced non-small-cell lung cancer: a phase cisplatin/vinorelbine (CV) versus CV alone in the first-line cancer, Cancer Chemother Pharmacol, 2001;48:356–60.
III trial of the European Organization for Research and treatment of patients with advanced non-small cell lung 43. Takeda K, Negoro S, et al., Docetaxel (D) versus docetaxel
Treatment of Cancer Lung Cancer Group-EORTC 08975, J Clin cancer (NSCLC), J Clin Oncol, 2008;26(18S): Abstract 3. plus gemcitabine (DG) for second-line treatment of non-small
Oncol, 2003;21(21): 3909–17. 27. Hurwitz H, Fehrenbacher L, et al., Bevacizumab plus cell lung cancer (NSCLC): results of a JCOG randomized trial
8. Schiller JH, Harrington D, et al., Eastern Cooperative irinotecan, fluorouracil, and leucovorin for metastatic (JCOG0104), J Clin Oncol, 2004;22(14S): Abstract 7034.
Oncology Group. Comparison of four chemotherapy regimens colorectal cancer, N Engl J Med, 2004;350:2335–4. 44. Lai CL, Tsai CM, et al., Phase II randomized trial of tri-weekly
for advanced non-small-cell lung cancer, N Engl J Med, 2002; 28. Dowlati A, Gray R, et al., Cell adhesion molecules, vascular versus day 1 and 8 weekly docetaxel as a second line
346(2):92–8. endothelial growth factor, and basic fibroblast growth factor treatment of advanced non-small cell lung cancer, Jpn J Clin
9. Kosmidis P, Mylonakis N, et al., Paclitaxel plus carboplatin in patients with non-small cell lung cancer treated with Oncol, 2005; 35:700–706.
versus gemcitabine plus paclitaxel in advanced non-small-cell chemotherapy with or without bevacizumab – an Eastern 45. Chen YM, Shih JF, et al., A randomised trial of different
lung cancer: a phase III randomized trial, J Clin Oncol, Cooperative Oncology Group study, Clin Cancer Res, 2008;1 docetaxel schedules in non-small cell lung cancer patients
2002;20:3578–85 4:1407–12. who failed previous platinum-based chemotherapy, Chest,
10. Georgoulias V, Papadakis E, et al., Platinum-based and non- 29. Manegold C, von Pawel J, et al., Randomized double-blind, 2006;129: 1031–8.
platinum-based chemotherapy in advanced non-small-cell multicentre phase III study of bevacizumab in combination 46. Chou KT, Chen YM, et al., Phase II randomized study of
lung cancer: a randomised multicentre trial, Lancet, with cisplatin and gemcitabine in chemotherapy-naïve weekly docetaxel alone or plus UFUR treatment in non-small
2001;357: 1478–84. patients with advanced or recurrent non-squamous non-small cell lung cancer patients who failed previous chemotherapy,
11. Scagloiotti GV, De Marinis F, et al., Phase III randomised trial cell lung cancer (NSCLC): Bo17704, J Clin Oncol, Lung Cancer, 2008;59:64–8.
comparing three platinum-based doublets in advanced non- 2007;25(18S): Abstract LBA7514. 47. Perng RP, Shih JF, et al., A phase II study of single-agent
small-cell lung cancer, J Clin Oncol, 2002;20:4285–91. 30. Wakelee H, Antibodies to vascular endothelial growth factor docetaxel chemotherapy for non-small cell lung cancer, Jpn J
12. Douillard JY, Fossella F, et al., Comparison of docetaxel and in non-small cell lung cancer, J Thor Oncol, 2008;3(Suppl. 2): Clin Oncol, 2000;30:429–34.
vinca alkaloid, alone or in combination with other S113–18. 48. Kunitoh H, Watanabe K, et al., Phase II trial of docetaxel in
chemotherapy agents, in the first-line treatment of advanced 31. Manegold C, von Pawel J, et al., BO17704 (AVAiL): A phase previously untreated advanced non-small-cell lung cancer: a
non-small cell lung cancer (NSCLC): A meta-analysis, J Clin III randomised study of first-line bevacizumab combined with Japanese cooperative study, J Clin Oncol, 1996;14:1649–55.
Oncol, 2006;24(18S): Abstract 7034. cisplatin/gemcitabine (CG) in patients with advanced or 49. Millward MJ, Boyer MJ, et al., Docetaxel and carboplatin is
13. Scagliotti GV, Parikh P, et al., Phase II study comparing recurrent non-squamous, non-small cell lung cancer (NSCLC), an active regimen in advanced non-small-cell lung cancer: a
cisplatin plus gemcitabine with cisplatin plus pemetrexed in Ann Oncol, 2008;19(Suppl. 8): Abstract LBA1. phase II study in Caucasian and Asian patients, Ann Onc,
chemotherapy-naïve patients with advanced-stage non-small- 32. Shepherd FA, Dancey J, et al., Prospective randomized trial of 2003;14(3):449–54.
cell lung cancer, J Clin Oncol, 2008;26:3543–51. docetaxel versus best supportive care in patients with non- 50. Zalcberg J, Millward MJ, et al., Phase II study of docetaxel
14. Cardiello F, De Vita F, Orditura M, Tortora G, The role of small-cell lung cancer previously treated with platinum-based (Taxotere
®
) and cisplatin in advanced non-small-cell lung
EGFR inhibitors in nonsmall cell lung cancer, Curr Opin Oncol, chemotherapy, J Clin Oncol, 2000;18:2095–2103. cancer, J Clin Oncol, 1998;16:1948–53.
2004; 16:130–35. 33. Fossella FV, de Vore R, et al., Randomized phase III trial of 51. Lilenbaum RC, Schwartz MA, et al., Phase II trial of weekly
15. Perez-Soler R, Chachoua A, et al., Determinants of tumour docetaxel versus vinorelbine or isosfamide in patients with docetaxel in second-line therapy for non-small cell lung
response and survival with erlotinib in patients with non- non-small-cell lung cancer previously treated with platinum- carcinoma, Cancer, 2001;92:2158–63.
small-cell lung cancer, J Clin Oncol, 2004;22:3238–47. containing chemotherapy regimens: The TAX320 Non-Small- 52. Valerio MR, Russo A, et al., Weekly docetaxel as second line
16. Shepherd FA, Rodrigues Pereira J, et al., Erlotinib in Cell Lung Cancer Study Group, J Clin Oncol, therapy in non-small cell lung cancer: an interim analysis of a
previously treated non-small-cell lung cancer, N Engl J Med, 2000;18:2354–62. phase II study, Lung Cancer, 2001;34:S31–S35.
2005;353: 123–32. 34. Hanna N, Shepherd FA, et al., Randomized phase III trial of 53. Hirata T, Kawashita F, et al., Phase I/II study of weekly
17. Herbst RS, Prager D, et al., TRIBUTE: A phase III trial of pemetrexed versus docetaxel in patients with non-small-cell docetaxel in patients with previously treated non-small cell
erlotinib hydrochloride (OSI-774) combined with carboplatin lung cancer previously treated with chemotherapy, J Clin lung cancer (NSCLC), J Clin Oncol, 2004;22(14S): Abstract
and paclitaxel chemotherapy in advanced non-small-cell lung Oncol, 2004;22:1589–97. 7243.
cancer, J Clin Oncol, 2005;23:5892–9. 35. Bunn PA, Thatcher N, Conclusion, The Oncologist, 2008: 54. Yamamoto N, Tamura T, et al., Correlation between
18. Miller VA, Herbst R, et al., Long survival of never smoking 13(1):37–46. docetaxel clearance and estimated cytochrome P450 activity
non-small cell lung cancer (NSCLC) patients treated with 36. Kim ES, Hirsch V, et al., Gefitinib versus docetaxel in by urinary metabolite of exogenous cortisol, J Clin Oncol,
erlotinib HCl (OSI-774) and chemotherapy: Sub-group previously treated non-small-cell lung cancer (INTEREST): a 2000;18: 2301–8.
analysis of TRIBUTE, J Clin Oncol, 2004;22(14S): Abstract randomised phase III trial, Lancet, 2008;372:1809–18. 55. Goh BC, Lee SC, et al., Explaining interindividual variability
7061. 37. Fehrenbacher L, O’Neill V, et al., A phase II, multicentre, of docetaxel pharmacokinetics and pharmacodynamics in
19. Gatzemeier U, Pluzanska A, et al., Phase III study of erlotinib randomized clinical trial to evaluate the efficacy and safety of Asians through phenotyping and genotyping strategies, J Clin
in combination with cisplatin and gemcitabine in advanced bevacizumab in combination with either chemotherapy Onc, 2002;20:3683–90.
non-small-cell lung cancer: The Tarceva Lung Cancer (docetaxel or pemetrexed) or erlotinib hydrochloride 56. Lin Y, Anderson G, et al., Differences in the urinary excretion
Investigation Trial, J Clin Oncol, 2007;25:1545–52. compared with chemotherapy alone for treatment of of 6-beta-hydroxycortisol/cortisol between Asian and
20. Giaccone G, Herbst RS, et al., Gefitinib in combination with recurrent or refractory non-small cell lung cancer, J Clin Caucasian women, J Clin Pharmacol, 1999;39:578–82.
gemcitabine and cisplatin in advanced non-small-cell lung Oncol, 2006; 24(Suppl. 18): Abstract 7062.
cancer: A phase III trial – INTACT1, J Clin Oncol, 2004;22: 38. Herbst RS, O'Neill VJ, et al., Phase II study of efficacy and
40 ASIA-PACIFIC ONCOLOGY & HAEMATOLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100